Le Lézard
Classified in: Health
Subject: POL

BeneCard PBF Disrupts PBM Market by Offering Full Pass Through of Rebates


MECHANICSBURG, Pa., July 11, 2018 /PRNewswire/ -- As national attention focuses more strongly on pharmacy benefit managers (PBMs) and drug costs, the presidential administration has proposed PBMs pass through at least 33% of all rebates collected on drugs covered by Medicare Part D. BeneCard PBF already offers full pass-through of the rebates it receives to its clients. 

The call for rebate pass-through is based on concerns that PBMs retain undefined drug rebate amounts for themselves, adding to their profits rather than lowering prices for patients and plan sponsors. BeneCard PBF believes in a more transparent approach to rebates and pharmacy benefit management. The company offers full pass-through arrangements that help plan sponsors clearly see how prescription benefit dollars are being spent. Under BeneCard PBF's transparent model, clients benefit from immediate impact from negotiated improvements in both drug discounts and rebates.

BeneCard PBF's clinically focused model keeps patients at the forefront. Members get the right medication for them, not the medications that create profits for the PBM through rebate retention. The company's experience has proven that a business model driven by patient-centric clinical coordination of care, not rebates, reduces costs.

The result of this focus clearly show in BeneCard PBF's trend. Lower prescription trends equate to savings that compound year after year. Although drug costs continue to rise, and the PBM industry's average seven-year prescription trend sits at 47.80%, BeneCard PBF's seven-year trend is less than half that at 19.67%. Thanks to its clinically focused, ethical and transparent approach combined with adaptable, advanced technology, BeneCard PBF continually outperforms the industry.

BeneCard PBF is a national, full-service Prescription Benefit Manager that excels in patient-centric care. The company defies industry norms and delivers clinically focused, ethical and purely transparent PBM solutions. To achieve proven lower net costs, the company aligns its interests with its clients' needs through proactive clinical programs and award-winning customer service. For more information, visit www.benecardpbf.com or contact Hugh Gallagher at 267-605-6428.

SOURCE BeneCard PBF


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: